Compare DexCom, Inc. (DXCM) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Plby Group Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: DexCom, Inc. is far larger — about 269.5× Plby Group Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Plby Group Inc for 24 Days on average.
| DXCM | PLBY | |
|---|---|---|
Market Cap | $31.86B | $118.21M |
Volume | 3,607,070 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $2.71 |
52-Week Low | $54.84 | $0.99 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $31.32B | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
PLBY Group trades at $0.98, down 3.66% today, with a bearish technical signal from moving averages and oscillators. The company shows improving fundamentals with revenue stabilizing around $121 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent leadership appointments signal strategic growth initiatives, while analyst consensus remains strongly positive with 75% buy ratings.
The outlook suggests cautious optimism as PLBY transitions toward profitability, projected to reach net income of $283,000 in 2026. Key risks include high debt levels with 59.52% debt-to-asset ratio and persistent negative shareholder equity. The stock offers potential upside if turnaround execution succeeds, but remains vulnerable to operational challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
